The Full form of TCH is Taxotere, Carboplatin and Herceptin. TCH is a chemotherapy regimen used to treat HER2 (Human Epidermal Growth Factor receptor 2) -positive breast cancer. It is a combination of two chemotherapy medicines; Paclitaxel (Taxol) or Docetaxel (Taxotere), taxane chemotherapy medicines, Carboplatin (Paraplatin), a platinum-type chemotherapy and a targeted therapy Trastuzumab (Herceptin). Trastuzumab is a type of targeted therapy called a monoclonal antibody. It attaches to HER2 proteins and can kill HER2-positive cancer cells. Docetaxel and paclitaxel work by damaging the structure that supports cancer cells. This stops the cancer cells from dividing and growing. Trastuzumab (H) attaches to HER2 proteins on the surface of HER2-positive cancer cells, and blocks the signals that cause the cancer cells to multiply. TCH is used as after surgery, adjuvant therapy or neoadjuvant therapy, before surgery, for early-stage breast cancer that is HER2-positive and node-positive, when the cancer has traveled to lymph nodes and HER2-positive, node-negative, when the cancer hasn’t traveled to lymph nodes. You and your doctor will discuss the best chemotherapy treatment for your situation. All three medicines are given by vein. Trastuzumab can be given first, followed by docetaxel or paclitaxel and carboplatin. It’s also common to receive all three medicines at once.